Clinical trial
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's…
NCT00426855 · Peter Moosmann, Other · Completed
Key facts
| NCT number | NCT00426855 |
|---|---|
| Title | Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) |
| Official title | Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study |
| Lead sponsor | Peter Moosmann, Other |
| Collaborators | Kantonsspital Aarau |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Bendamustine, Bortezomib |
| Enrollment | 12 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 25, 2007 |
| Last update posted | Apr 3, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: